Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORKA-001 in Healthy Participants
NCT06698939Phase 1Completed
- Sponsor
- Oruka Therapeutics
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing ORKA-001 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 1 year. Started Dec 2024; status: completed.
02
Drugs
orka-001
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06698939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698939.